Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients - Wikidata - awgldk - TriplyDB

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients

http://www.wikidata.org/entity/Q35995048

about

The influence of vitamin D analogs on calcification modulators, N-terminal pro-B-type natriuretic peptide and inflammatory markers in hemodialysis patients: a randomized crossover study.Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients.Vascular calcification on plain radiographs is associated with carotid intima media thickness, malnutrition and cardiovascular events in dialysis patients: a prospective observational study.Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients.Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk.Coronary artery calcification in chronic kidney disease: An update.Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis.Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients.Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies.Osteoprotegerin Is the Strongest Predictor for Progression of Arterial Calcification in Peritoneal Dialysis Patients.Targeting Immunity in End-Stage Renal Disease.Uremic Serum Impairs Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stromal Cells.Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification

P2860

Q34059805-7D508EF0-0496-4887-92FB-55B28D5956AD Q34502634-D91A2FF1-E144-452F-96C5-4EBA34302E06 Q34547461-A5C0C295-050A-4CAF-86AB-200FFAD4A604 Q34566734-36633A6B-EC66-4F7C-94E3-1201731C59FD Q34768588-14DD1946-3735-4F5E-804C-12C360AF067D Q35030290-4C05B22F-032B-4046-8410-54914B6125F5 Q35152692-231CCBD2-0EA4-43A2-99CE-C14D3F2B9186 Q35279609-537EB828-3A78-4363-8652-1A29AB422DBC Q37625447-999ABFE1-B01D-4B30-A46A-2B6A10EE2CC4 Q37722763-1954867B-0103-4192-9C63-DF94077F2F97 Q39056902-24E01CD7-262A-43F9-BCE8-51D2CFEF6855 Q39369106-4AE4830C-7B0F-4C01-8EE8-E09056E5B1F2 Q40084826-EAD61383-A539-40CF-A8EB-EA874A5B75C3 Q41524527-53ECF982-BD76-4485-B327-7AAECCFB96C7 Q44657342-4C426C57-7935-466D-A2F5-11BA80663A42 Q47823030-5AC82A81-8894-4CCF-BE17-A21B7A8889DF Q50872135-EBE7EF8C-B56E-4EAC-844F-BE99896F27C5 Q51010560-C8A72732-FAD6-418C-BC17-3FF64F921B8C Q57580529-FA21B3B8-5E23-42ED-B0EB-90E83B359176 Q58786857-BD4DFFBF-A48A-460D-9908-E0CA0FFDA236

P2860

Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients

http://www.wikidata.org/entity/Q35995048

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@ast

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@en

type

label

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@ast

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@en

prefLabel

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@ast

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@en

P1433

Q35995048-D7DF08B5-03C2-4B40-975E-545132916562

P1476

Q35995048-BA99A318-B5FA-427B-8AE9-94B273CDBF8B

P2093

Q35995048-12FFF010-9865-42D0-BA89-993E06DC0786

Q35995048-3A564888-F006-42C0-8BF7-908C5E133A50

Q35995048-59E2FA98-A580-4E1E-916D-F7FDFAC54B45

Q35995048-770363F1-23CD-4D37-BC10-CB685B107A82

Q35995048-8351AF95-A7C1-449C-9606-4528F0CE5496

Q35995048-A79F31F4-3285-4518-AA60-4C520942DA1F

Q35995048-E7C6E749-DC3B-41A6-85EC-B78BBA44202A

Q35995048-EA1A82DE-F3D4-49F2-A1B5-1C9CA0186E03

P2860

Q35995048-044A0FD7-E10D-4B6A-80BC-4982947FFE3E

Q35995048-0954A384-E6F5-491F-9F8D-B4B0B122E3A4

Q35995048-0ED70C68-2DC2-4712-B55B-5AE944A2422D

Q35995048-152BA97B-77D2-43E5-9ACF-814F664BC4F7

Q35995048-1F914EBC-F7A4-4803-B75B-FD50D93FF64D

Q35995048-2461F472-DE05-425F-BB9D-6AA3866B6967

Q35995048-25C0DEF1-7862-4FC8-BBB5-9C262FA5DE7B

Q35995048-2952E822-098F-4271-8972-EAA02E4C3ABD

Q35995048-4182A6CE-3148-4307-908E-E654EC3EB0C7

Q35995048-4A77C741-098F-47FD-9FF3-0EC9B7AD13FE

P304

Q35995048-2B8F7666-4B9B-4552-BF2C-8576773AAD2E

P31

Q35995048-0552A6B6-162B-4B24-8F3E-D679356D8865

P356

Q35995048-E23340A3-5FB3-415D-B88C-8967D9FB2A84

P433

Q35995048-55350FA4-1271-42B5-B5D5-D3CA0EE92CC3

P478

Q35995048-632129EA-EF56-4CF8-A065-F6C1FED1AC6F

P577

Q35995048-9471DEFB-2D26-435A-8CFF-DC2C53649E60

P698

Q35995048-E3F1A63F-2046-423C-A4EF-27F21A3801A0

P932

Q35995048-DF793207-44D9-4D64-8EFD-C7F8FD4D5E28

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Osteoprotegerin/RANKL axis and ...... ation in hemodialysis patients

@en

P2093

Abdulkadir Unsal

http://www.w3.org/2001/XMLSchema#string

Abdullah Ozkok

http://www.w3.org/2001/XMLSchema#string

Alaattin Yildiz

http://www.w3.org/2001/XMLSchema#string

Alper Ozel

http://www.w3.org/2001/XMLSchema#string

Gaye Erten

http://www.w3.org/2001/XMLSchema#string

Gonca Karahan

http://www.w3.org/2001/XMLSchema#string

Tamer Sakaci

http://www.w3.org/2001/XMLSchema#string

Yasar Caliskan

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

Recent advances in multifactorial regulation of vascular calcification.

Vascular calcification and bone disease: the calcification paradox.

Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis

Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD.

Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation

Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.

P304

965-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.11191111

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22490874

http://www.w3.org/2001/XMLSchema#string

P932

3362313

http://www.w3.org/2001/XMLSchema#string